Table 4 Analysis of factors associated with tumor recurrence rate.

From: A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices

Parameters

 

Univariate

Multivariate

HR

95% CI

p

HR

95% CI

p

Age (years)

 > 65 vs.≦65

1.318

0.970–1.791

0.077

   

Sex

Male vs. Female

1.101

0.795–1.526

0.563

   

HBsAg (+)

No vs. Yes

1.282

0.944–1.739

0.111

   

Anti-HCV (+)

Yes vs. No

1.163

0.856–1.580

0.334

   

Albumin (g/dL)

≦ 3.5 vs. > 3.5

1.437

1.058–1.951

0.02

   

Bilirubin (mg/dL)

 > 1.6 vs.≦1.6

1.333

0.907–1.958

0.143

   

ALT (U/L)

 > 40 vs.≦40

0.960

0.705–1.306

0.794

   

ALK-P (U/L)

 > 100 vs.≦100

0.982

0.697–1.385

0.919

   

PT-INR

 > 1.1 vs.≦1.1

1.400

1.022–1.918

0.036

   

AFP (ng/ml)

 > 20 vs.≦20

1.089

0.801–1.482

0.585

   

Multiple Tumors

Yes vs. No

1.425

1.005–2.019

0.047

1.421

1.002–2.016

0.049

Tumor size (cm)

 > 3 vs.≦3

0.946

0.678–1.321

0.746

   

Treatment modality

RFA vs. SR

1.586

1.130–2.225

0.008

1.583

1.128–2.221

0.008

PLT (× 1000/mm3)

≦ 100 vs. > 100

0.915

0.658–1.273

0.599

   

ALBI grade

2 + 3 vs. 1

1.406

1.001–1.974

0.049

   

All peri-procedural morbidity

Yes vs. No

1.229

0.748–2.017

0.416

   

Major morbidity

Yes vs. No

1.611

0.659–3.939

0.296

   

High risk EV

Yes vs. No

0.930

0.680–1.274

0.653

   

Presence of GV

Yes vs. No

1.216

0.823–1.795

0.326

   

EV prophylaxis

No vs Yes

0.951

0.701–1.289

0.746

   
  1. HR hazard ratio; CI confidence interval; HBsAg hepatitis B surface antigen; HCV hepatitis C virus; ALT alanine aminotransferase; ALK-P alkaline phosphate; PT INR prothrombin time international normalized ratio; AFP alpha-fetoprotein; RFA radiofrequency ablation; SR surgical resection; PLT platelet; ALBI Albumin-Bilirubin; EV grade: Esophageal varices grade: F1-RCS: F1 without red color sign; F1 + RCS F1 with red color sign; GV gastric varices.
Back to article page